AT(N) biomarker profiles and Alzheimer’s disease in People with Down syndrome
David Egan, born with Down syndrome at St. Mary’s Hospital in Madison in 1977, has spent much of his life proving that there isn’t much he — or others with intellectual disabilities — can’t do, given an opportunity.
The National Institutes of Health-funded Alzheimer’s Biomarkers Consortium – Down Syndrome (ABC-DS), a large multi-center research initiative to find biomarkers to track Alzheimer’s disease in Down syndrome. The Waisman Center is part of this multi-site …
Structural pathologies, such as brain, are present at birth in Down syndrome (trisomy 21), reflecting embryonic origins that are generally associated with smaller organs or reduced growth.
Be included! Families of children with Down syndrome are invited to participate in our new study about genetics and health. The Waisman BioLibrary is recruiting youth with Down syndrome ages 0 – 17 years. Families …
PET amyloid [11C]PiB imaging has revealed early detection of Aβ in the striatum in individuals with Down Syndrome (DS), a group carrying genetic risk for AD.
Boxplots depicting median and variation for episodic memory score by PET amyloid beta (Aβ–vs. Aβ+) and tau (TLvs. TH) status in Braakregions I to VI.
By Emily Leclerc, Waisman Science Writer The month of October is Down Syndrome Awareness Month and is dedicated to not only raising awareness about Down syndrome but also to celebrating the abilities and accomplishments of …
Waisman Center researchers are creating a new approach to study how changes to brain development in the womb result in intellectual disability in people with Down syndrome.
Down syndrome (DS, trisomy 21) is characterized by intellectual impairment at birth and Alzheimer’s disease (AD) pathology in middle age. As individuals with DS age, their cognitive functions decline as they develop AD pathology.